Editorial
|
|
|
|
|
Taking sufficient time to evaluate innovations
|
|
|
|
Marketing Authorisations
|
|
|
|
|
An excessively dangerous and inadequately evaluated hypouricaemic drug
|
|
|
|
|
|
|
|
|
|
|
|
Chronic myeloid leukaemia in treatment failure: major toxicity
|
|
|
|
|
|
|
|
|
|
|
|
Just another anticonvulsant for partial epilepsy: no progress
|
|
|
|
Adverse Effects
|
|
|
|
|
Mainly cytotoxic and photosensitising drugs
|
|
|
|
|
|
|
|
|
|
Unjustified risk of thromboembolism
|
|
|
|
|
|
|
|
|
|
Keeping iron dextran on the European market is absurd
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Dimeticone is the pediculicide of choice
|
|
|
|
|
|
|
|
|
|
The Physician's Health study
|
|
|
|
|
|
|
|
|
|
Amoxicillin does not speed recovery
|
|
|
|
Outlook
|
|
|
|
|
Changing perceptions of radiological risks
|
|
|
|
|
|
|
|
|
|
Partnering with industry is not a trivial matter
|
|
|
|
|
|